Specify a stock or a cryptocurrency in the search bar to get a summary
Abbisko Cayman Ltd
2256Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China. Address: Building 3, Shanghai, China
Analytics
WallStreet Target Price
88.58 HKDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 2256
Dividend Analytics 2256
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2256
Stock Valuation 2256
Financials 2256
Results | 2019 | Dynamics |